ExtraLife
A Six-Layer Investigational Framework Combining Peptides, Stem Cells, Molecular Hydrogen, Neural Plasticity, AI, and Photobiomodulation
v2.0 in progress — will include MDPs (Humanin, MOTS-c, SS-31) and LLLT protocol
The Problem
Tinnitus is a multi-system condition being treated with single-mechanism interventions. The ear, the brain, the nervous system, the inflammatory cascade — they're all involved. Yet every existing treatment targets only one. We're changing that.
The Protocol
Each layer targets a different mechanism of tinnitus. Together, they create the first truly multi-system investigational approach.
A targeted stack of neuroprotective and regenerative peptides designed to repair cochlear nerve damage, reduce neuroinflammation, and create a receptive biological environment for downstream interventions.
Body Protection Compound-157 promotes angiogenesis, upregulates growth hormone receptors, and has demonstrated neuroprotective effects in multiple animal models. Dosing: 250-500 mcg subcutaneous, 2x daily.
Thymosin Beta-4 fragment promotes cell migration, reduces systemic inflammation, and supports tissue repair across multiple organ systems including the CNS. Dosing: 2.5-5 mg subcutaneous, 2x weekly.
Copper peptide that remodels damaged tissue, promotes collagen synthesis, and has demonstrated anti-inflammatory and antioxidant properties relevant to inner ear recovery. Dosing: 1-2 mg subcutaneous daily.
Synthetic analog of tuftsin with anxiolytic and nootropic properties. Modulates GABA and serotonin systems, directly addressing the anxiety-tinnitus feedback loop. Dosing: 250-500 mcg intranasal, 2x daily.
A new class of peptides encoded within mitochondrial DNA, showing direct protective effects on cochlear hair cells — a breakthrough for tinnitus research.
A 24-amino-acid mitochondrial-derived peptide. The synthetic analog HNG (Humanin S14G) has demonstrated direct protective effects on cochlear hair cells exposed to ototoxic damage. Mechanism: Activates AKT survival pathway in cochlear cells.
A 16-amino-acid mitochondrial-derived peptide that activates AMPK and regulates antioxidant response genes. Demonstrated protective effects on cochlear hair cells. Reduces pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and supports mitochondrial homeostasis. Mechanism: AMPK activation, NRF2 antioxidant response, anti-inflammatory.
A tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane, stabilizing structure and preventing the mitochondrial collapse that triggers hair cell death. SS-31 conjugated nanoparticles showed mitochondrial-specific accumulation in cochlear hair cells with favorable survival rates. Mechanism: Cardiolipin binding, mitochondrial membrane stabilization, ATP optimization.
A targeted stack of neuroprotective and regenerative peptides designed to repair cochlear nerve damage, reduce neuroinflammation, and create a receptive biological environment for downstream interventions.
Body Protection Compound-157 promotes angiogenesis, upregulates growth hormone receptors, and has demonstrated neuroprotective effects in multiple animal models. Dosing: 250-500 mcg subcutaneous, 2x daily.
Thymosin Beta-4 fragment promotes cell migration, reduces systemic inflammation, and supports tissue repair across multiple organ systems including the CNS. Dosing: 2.5-5 mg subcutaneous, 2x weekly.
Copper peptide that remodels damaged tissue, promotes collagen synthesis, and has demonstrated anti-inflammatory and antioxidant properties relevant to inner ear recovery. Dosing: 1-2 mg subcutaneous daily.
Synthetic analog of tuftsin with anxiolytic and nootropic properties. Modulates GABA and serotonin systems, directly addressing the anxiety-tinnitus feedback loop. Dosing: 250-500 mcg intranasal, 2x daily.
A new class of peptides encoded within mitochondrial DNA, showing direct protective effects on cochlear hair cells — a breakthrough for tinnitus research.
A 24-amino-acid mitochondrial-derived peptide. The synthetic analog HNG (Humanin S14G) has demonstrated direct protective effects on cochlear hair cells exposed to ototoxic damage. Mechanism: Activates AKT survival pathway in cochlear cells.
A 16-amino-acid mitochondrial-derived peptide that activates AMPK and regulates antioxidant response genes. Demonstrated protective effects on cochlear hair cells. Reduces pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and supports mitochondrial homeostasis. Mechanism: AMPK activation, NRF2 antioxidant response, anti-inflammatory.
A tetrapeptide that binds to cardiolipin in the inner mitochondrial membrane, stabilizing structure and preventing the mitochondrial collapse that triggers hair cell death. SS-31 conjugated nanoparticles showed mitochondrial-specific accumulation in cochlear hair cells with favorable survival rates. Mechanism: Cardiolipin binding, mitochondrial membrane stabilization, ATP optimization.
The Timeline
A phased approach that layers interventions strategically — priming the body before the primary regenerative intervention, then optimizing over time.
Comprehensive baseline assessment followed by peptide therapy and molecular hydrogen initiation. Building the biological foundation for stem cell intervention.
After 6 weeks of peptide priming, the tissue environment is optimized for stem cell therapy. This is the primary regenerative intervention window.
The longest phase — layering in neural plasticity interventions while continuing regenerative support. This is where the multi-mechanism approach differentiates from single-treatment trials.
Final assessment phase. Measuring outcomes, tapering interventions, and establishing the maintenance protocol for sustained results.
Measurement Framework
Every data point matters. Our measurement protocol captures auditory, inflammatory, neurological, and quality-of-life biomarkers across the full 24 weeks.
| Biomarker | Frequency | Purpose |
|---|---|---|
| Pure-Tone Audiogram | Baseline, 6w, 12w, 18w, 24w | Objective hearing thresholds |
| THI Score | Weekly | Subjective tinnitus severity |
| Tinnitus Pitch Match | Baseline, 12w, 24w | Frequency characterization |
| OAE (Otoacoustic Emissions) | Baseline, 12w, 24w | Outer hair cell function |
| Biomarker | Frequency | Purpose |
|---|---|---|
| hs-CRP | Every 6 weeks | Systemic inflammation |
| IL-6 | Every 6 weeks | Pro-inflammatory cytokine |
| TNF-alpha | Every 6 weeks | Neuroinflammation marker |
| Biomarker | Frequency | Purpose |
|---|---|---|
| HRV (RMSSD) | Daily | Autonomic regulation |
| EEG / Neurofeedback | 2x weekly | Auditory cortex activity |
| GAD-7 | Weekly | Anxiety levels |
| PSS-10 | Weekly | Perceived stress |
| Biomarker | Frequency | Purpose |
|---|---|---|
| Sleep Onset Latency | Daily | Time to fall asleep |
| Deep Sleep % | Daily | Sleep architecture quality |
| WHOQOL-BREF | Baseline, 12w, 24w | Quality of life |
Fund This Research
This protocol is investigated through the ExtraLife Collective. No corporate gatekeepers. No paywalled results. Every dollar tracked. Every finding published.
The ExtraLife Tinnitus Research Protocol is an investigational framework. It has not been approved by the FDA or any regulatory body for the treatment of tinnitus. All interventions described herein are based on published peer-reviewed research and are being investigated under IRB-approved protocols where applicable. Individual results may vary. This protocol does not constitute medical advice, diagnosis, or treatment. Peptide therapy, stem cell therapy, psilocybin protocols, and molecular hydrogen therapy are investigational and should only be pursued under physician supervision within a clinical research context. Research fund contributions are not tax-deductible.
Get updates on protocol development, trial enrollment, and published findings.
Monthly research updates, protocol insights, and community events. No spam.